PC
TEVA icon

Parrish Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Parrish Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.93M Sell
97,153
-16,584
-15% -$534K 2.61% 4
2025
Q4 		$3.55M Buy
+113,737
New +$2.8M 3.21% 3

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parrish Capital's TEVA Position: Q1 2026 in Review

Parrish Capital reduced its Teva Pharmaceuticals (TEVA) stake by 15% in Q1 2026, selling an estimated $534K and leaving 97,153 shares worth $2.93M. The position accounts for 2.61% of the portfolio, ranked #4.

Parrish Capital first reported a position in TEVA in Q4 2025 and has held it in 2 quarters since. The position peaked at $3.55M in Q4 2025. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Parrish Capital held 97,153 shares of Teva Pharmaceuticals worth $2.93M as of Q1 2026.
  • Parrish Capital sold 16,584 Teva Pharmaceuticals shares in Q1 2026, an estimated $534K.
  • Teva Pharmaceuticals made up 2.61% of Parrish Capital's portfolio in Q1 2026, its #4 holding.
  • Parrish Capital first reported a position in Teva Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Parrish Capital's Teva Pharmaceuticals position peaked at $3.55M in Q4 2025.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Parrish Capital's 13F filing for Q1 2026, filed 28 Apr 2026.